Company Overview
About Oto
Oto is a London-based digital health company providing clinically validated, app-based CBT (cognitive behavioral therapy) treatment for tinnitus — the persistent ringing, buzzing, or hissing in the ears that affects 15% of the global population (750 million+ people) with no pharmaceutical cure — delivering structured therapeutic programs designed by tinnitus specialists that help patients manage and reduce tinnitus distress through evidence-based psychological and sound therapy techniques. Founded and backed with £2.8 million in seed funding raised in 2022, Oto demonstrated in the DEFINE Trial (the largest randomized controlled trial for any digital tinnitus program) that 86% of users experience measurable benefits within one month of the program.
Business Model & Competitive Advantage
Oto's therapeutic model is grounded in Tinnitus Retraining Therapy (TRT) and CBT — the gold standard clinical approaches that retrain the brain's response to tinnitus sound rather than attempting to eliminate the sound itself. The app-based delivery makes TRT and CBT accessible without specialist referrals: traditional tinnitus CBT requires sessions with a specialized audiologist or psychologist (typically 6-12 sessions at £100-200 each), limiting access to patients in major cities with specialist waitlists. Oto's structured 8-week program delivers the same therapeutic framework through daily app exercises, educational content about tinnitus neuroscience, sound therapy (white noise, nature sounds, notched audio therapy), and mood and symptom tracking.
Competitive Landscape 2025–2026
In 2025, Oto competes in the digital tinnitus and hearing health market with Widex Sound Relief (hearing aid manufacturer's tinnitus app), Neuromod Lenire (bimodal neuromodulation device for tinnitus, €100M raised), and ReSound Relief (GN Audio tinnitus management app) for tinnitus patient engagement and clinical validation. The NHS Long Term Plan for digital first care creates NHS partnership opportunities for Oto as a NICE-approved digital therapeutic. US expansion (planned for 2025) accesses the 50 million Americans with tinnitus who lack adequate clinical care options. The 2025 strategy focuses on NHS commissioning partnerships (prescribable digital therapeutic), US audiologist partnerships for clinical referral networks, and building the enterprise hearing health benefit channel for employers in high-noise industries (manufacturing, construction, military).
Recent Activity
View all →Material Event filed 2026-09-09
Material Event filed 2026-08-17
Material Event filed 2026-08-04
Material Event filed 2026-07-28
Material Event filed 2026-07-22
Quarterly Report filed 2026-07-22
Key Differentiators
Emerging Innovator
Oto is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Doximity
Doximity is a professional network and digital health platform purpose-built for licensed physicians and other healthcare professionals in the United States. With more than two million verified clinic
Zocdoc
Zocdoc operates a two-sided marketplace connecting patients with physicians, dentists, and mental health providers who accept their specific insurance and have real-time appointment availability. Pati
Epic Systems
Epic Systems Corporation was founded in 1979 by Judith Faulkner and is headquartered in Verona, Wisconsin, remaining privately held with Faulkner as majority owner. The company develops large-scale el
athenahealth
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on
Pfizer
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The compan
Moderna
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stép
Compare Oto with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Oto? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Oto Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Oto vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →